Tag: drugs

Ad hoc announcement pursuant to Art. 53 LR

BENGALURU, India, June 09, 2025 (GLOBE NEWSWIRE) -- RenaissThera Private Limited (“RenaissThera”), a Bengaluru-based biotechnology company, announced a major milestone in its obesity drug discovery program targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR). GIPR, an incretin receptor, is a validated target for peptide-based parenteral therapies where both stimulation and inhibition has shown efficacy in treating obesity and its co-morbidities. RenaissThera is developing novel, oral small molecules, both agonists and antagonists, as a more affordable and convenient alternative aiming to expand access for underserved populations in the global obesity market projected to reach USD 38 billion by 2032. Oral small molecules are more economical to manufacture and distribute than peptide-based obesity drugs. These molecules were designed and screened using proprietary AI and ML based platforms, followed by demonstrating in-vitro activity in cell lines and in-vivo activity to impact GIPR in mice to yield “Hits”. RenaissThera now is advancing these Hits to the Lead optimization program to select candidates for pre-IND studies.

MIAMI BEACH, Fla., June 09, 2025 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS) (“AirSculpt” or the “Company”), a national provider of premium body contouring procedures, today announced the launch of an underwritten public offering of 3,160,000 shares of its common stock. The underwriter will also have a 30-day option to purchase up to 474,000 additional shares of common stock. All of the shares of common stock in the offering are being sold by the Company.

National TV Segment Highlights FDA-Approved Treatment for Rosacea

The global Excipients Market, valued at $7.8 Billion in 2024, is projected to reach $10.2 Billion by 2030, growing at a CAGR of 4.6%. This comprehensive report analyzes key trends, drivers, and forecasts, emphasizing the essential role of excipients in pharmaceutical formulations. Discover how excipients enhance drug efficacy and patient experience, explore innovations like multifunctional excipients, and gain insights into regional growth trends, notably in the U.S. and China.

Atopic dermatitis is a chronic disease that disproportionately impacts communities of color